- Home
- CSGS vs KNSA Comparison
CSGS vs KNSA Comparison
Compare CSGS & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGS
- KNSA
- Stock Information
- Founded
- CSGS 1994
- KNSA 2015
- Country
- CSGS United States
- KNSA United Kingdom
- Employees
- CSGS N/A
- KNSA N/A
- Industry
- CSGS EDP Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CSGS Technology
- KNSA Health Care
- Exchange
- CSGS Nasdaq
- KNSA Nasdaq
- Market Cap
- CSGS 1.9B
- KNSA 1.9B
- IPO Year
- CSGS 1996
- KNSA 2018
- Fundamental
- Price
- CSGS $60.77
- KNSA $31.98
- Analyst Decision
- CSGS Buy
- KNSA Strong Buy
- Analyst Count
- CSGS 8
- KNSA 6
- Target Price
- CSGS $68.29
- KNSA $40.83
- AVG Volume (30 Days)
- CSGS 235.5K
- KNSA 648.4K
- Earning Date
- CSGS 08-06-2025
- KNSA 07-29-2025
- Dividend Yield
- CSGS 2.11%
- KNSA N/A
- EPS Growth
- CSGS 33.32
- KNSA N/A
- EPS
- CSGS 2.92
- KNSA 0.07
- Revenue
- CSGS $1,201,566,000.00
- KNSA $529,332,000.00
- Revenue This Year
- CSGS $3.32
- KNSA $37.21
- Revenue Next Year
- CSGS $3.56
- KNSA $6.10
- P/E Ratio
- CSGS $20.79
- KNSA $484.58
- Revenue Growth
- CSGS 3.08
- KNSA 56.18
- 52 Week Low
- CSGS $42.47
- KNSA $17.82
- 52 Week High
- CSGS $67.60
- KNSA $32.13
- Technical
- Relative Strength Index (RSI)
- CSGS 38.41
- KNSA 67.77
- Support Level
- CSGS $61.44
- KNSA $26.27
- Resistance Level
- CSGS $63.08
- KNSA $31.92
- Average True Range (ATR)
- CSGS 1.22
- KNSA 1.12
- MACD
- CSGS -0.11
- KNSA 0.37
- Stochastic Oscillator
- CSGS 5.97
- KNSA 97.11
About CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.